Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension.
diabetic microangiopathy
pulmonary hypertension
respiratory function
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
18
02
2019
revised:
12
03
2019
accepted:
19
03
2019
pubmed:
26
3
2019
medline:
4
4
2020
entrez:
26
3
2019
Statut:
ppublish
Résumé
In patients with type 1 and type 2 diabetes mellitus (DM), respiratory function abnormalities have been reported with regard to lung volumes, pulmonary diffusing capacity, control of ventilation, bronchomotor tone, and neuroadrenergic bronchial innervation. Indeed, the decrease in lung volumes and the impairment of diffusing capacity might have important clinical implications. Furthermore, there is an increasing evidence of a link between DM and pulmonary hypertension (PH) related to an involvement of the pulmonary vascular structures. These findings support the view of the lung as target organ in DM. In this paper, we briefly describe the main derangements of the respiratory system in DM and the inherent mechanisms.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3159Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Malte Rasmussen S, Brok J, Backer V, Francis Thomsen S, Meteran H. Association between chronic obstructive pulmonary disease and type 2 diabetes: a systematic review and meta-analysis. COPD. 2018;15(5):526-535.
López-de-Andrés A, de Miguel-Díez J, Jiménez-Trujillo I, et al. Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013. BMJ Open. 2017;7(1):e013097.
van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest. 2010;138(2):393-406.
Sonoda N, Morimoto A, Tatsumi Y, et al. A prospective study of the impact of diabetes mellitus on restrictive and obstructive lung function impairment: the Saku study. Metabolism. 2018;82:58-64.
Hsia CC, Raskin P. Lung function changes related to diabetes mellitus. Diabetes Technol Ther. 2007;9(Suppl 1):S73-S82.
Fuso L, Pitocco D, Longobardi A, et al. Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. Diabetes Metab Res Rev. 2012;28(4):370-375.
Ofulue F, Thurlbeck WM. Experimental diabetes and the lung: II. In vivo connective tissue metabolism. Am Rev Respir Dis. 1988;138(2):284-289.
Fuso L, Pitocco D, Condoluci C, et al. Decline of the lung function and quality of glycemic control in type 2 diabetes mellitus. Eur J Intern Med. 2015;26(4):273-278.
Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106(20):2555-2560.
Buchmann N, Norman K, Steinhagen-Thiessen E, Demuth I, Eckardt R. Lung function in elderly subjects with metabolic syndrome and type II diabetes: data from the Berlin Aging Study II. Z Gerontol Geriatr. 2015;Oct 27. [Epub ahead of print]
Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med. 2005;118:205-211.
Marvisi M, Bartolini L, del Borrello P, et al. Pulmonary function in non-insulin-dependent diabetes mellitus. Respiration. 2001;68(3):268-272.
Fuso L, Cotroneo P, Basso S, et al. Postural variations of pulmonary diffusing capacity in insulin-dependent diabetes mellitus. Chest. 1996;110(4):1009-1013.
Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest. 2005;128(5):3568-3571.
Makarevich AE, Valevich VE, Pochtavtsev AU. Evaluation of pulmonary hypertension in COPD patients with diabetes. Adv Med Sci. 2007;52:265-272.
Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30:904-911.
Naderi N, Boobejame P, Bakhshandeh H, Amin A, Taghavi S, Maleki M. Insulin resistance in pulmonary arterial hypertension, is it a novel disease modifier? Res Cardiovasc Med. 2014;3:e19710.
Heresi GA, Malin SK, Barnes JW, Tian L, Kirwan JP, Dweik RA. Abnormal glucose metabolism and high-energy expenditure in idiopathic pulmonary arterial hypertension. Ann Am Thorac Soc. 2017;14(2):190-199.
Amouzegar A, Mehran L, Hasheminia M, Kheirkhah Rahimabad P, Azizi F. The predictive value of metabolic syndrome for cardiovascular and all-cause mortality: Tehran Lipid and Glucose Study. Diabetes Metab Res Rev. 2017;33(1):e2819.
Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-S54.
Zafrir B, Adir Y, Shehadeh W, Shteinberg M, Salman N, Amir O. The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the "obesity paradox". Respir Med. 2013;107(1):139-146.
Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration. 1999;66(1):14-19.
Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853-859.
Lopez-Lopez JG, Moral-Sanz J, Frazziano G, et al. Type 1 diabetes-induced hyper-responsiveness to 5-hydroxytryptamine in rat pulmonary arteries via oxidative stress and induction of cyclooxygenase-2. J Pharmacol Exp Ther. 2011;338(1):400-407.
Hua H, Goldberg HJ, Fantus IG, Whiteside CI. High glucose-enhanced mesangial cell extracellular signal-regulated protein kinase activation and alpha1 (IV) collagen expression in response to endothelin-1: role of specific protein kinase C isozymes. Diabetes. 2001;50(10):2376-2383.
Arnold N, Koppula PR, Gul R, Luck C, Pulakat L. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One. 2014;9(7):e103284.
Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2007;116(2):163-173.
Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10(7):1220-1230.
Harik-Khan RI, Wise RA, Fozard JL. Determinants of maximal inspiratory pressure. The Baltimore Longitudinal Study of Aging. Am J Respir Crit Care Med. 1998;158(5):1459-1464.
Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006;1(3):253-260.
Taylor BJ, Johnson BD. The pulmonary circulation and exercise responses in the elderly. Semin Respir Crit Care Med. 2010;31(05):528-538.
Stam H, Hrachovina V, Stijnen T, Versprille A. Diffusing capacity dependent on lung volume and age in normal subjects. J Appl Physiol. 1994;76(6):2356-2363.